NewsRoom Articles - BioMedWire (BMW)

FridayNov 21, 2025 10:00 am

What Patients Need to Know About Exercising During Cancer Treatment

It may sound strange to speak of exercising and cancer treatment in the same breath, but experts and numerous studies have documented the immense value that patients can attain by integrating exercise into their schedule during the duration that they are receiving treatment for cancer. We address some of the queries that cancer patients may have about exercising during their treatment. First off, ASCO (American Society of Clinical Oncology) assembled experts that analyzed at least 100 clinical trials that explored any possible links between cancer treatment and exercise. These experts then published a report of their exercise recommendations back in…

ThursdayNov 20, 2025 10:00 am

Senator Sanders Suggests Six Other Ways to Address Health Crisis

On Tuesday, Senator Bernie Sanders authored a letter that he sent to Democrats in both chambers of Congress urging them to band together and support the Affordable Care Act. He wrote that a lot more can be done to improve healthcare in the country and made six suggestions that can help in attaining this objective. He appeals for an extension to the ACA tax credits designed to lower the cost of health insurance for people who aren’t eligible for Medicare yet they don’t have sufficient employer-provided medical cover. These tax credits were at the heart of the recently-ended government shutdown,…

ThursdayNov 20, 2025 9:00 am

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (“GAAP”) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (“JV”) entity GMP Bio, driven by a new independent valuation indicating a potential step-up in asset value. This key shift strengthens Oncotelic Therapeutics position…

TuesdayNov 18, 2025 10:00 am

Parent Explains Why it is Wrong to Say Vaccines Cause Autism

For a while, the media has been filled with claims that vaccines cause autism. These claims have been amplified by public figures like the U.S. Secretary of Health & Human Services, R. F. Kennedy Jr., as well as other public health leaders. Now a parent, Greg Scaduto, whose child is autistic, has come out to explain why such thinking is misguided and does more harm than good. He explains that these false narratives are founded in a failure to understand the difference between correlation and causation. He says many people quickly, and falsely, jump to the conclusion that when two…

FridayNov 14, 2025 10:00 am

Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer

A study that was recently published by a team of UC San Diego researchers has found that colon cancer patients who were also taking GLP-1 medications, such as Ozempic and Wegovy, had a 50% lower mortality rate when compared to colon cancer patients that didn’t use these medications. While these findings don’t suggest a causative effect, the researchers posit that the metabolic and anti-inflammatory effects of the GLP-1 drugs could be playing a role in reducing mortality among cancer patients. For their study, the team analyzed the medical records of at least 6,800 patients that had been diagnosed with colon…

FridayNov 14, 2025 9:45 am

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer with limited treatment options, and CEO John Climaco emphasized the company’s commitment to overcoming the blood-brain barrier, a key obstacle in brain cancer therapy. Lead candidate TPI 287, an abeotaxane, has shown early evidence of appearing to cross the blood-brain barrier and producing clinical responses. Phase 2 planning is underway following encouraging data from a Phase 1 combination study with bevacizumab (Avastin). The company’s repurposed global clinical network and regulatory progress position it for potential late-stage development in 2026. TPI 287 holds multiple Orphan Drug Designations, covering gliomas, neuroblastoma, and other CNS-related…

ThursdayNov 13, 2025 11:15 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership

Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths annually. The HeartBeam System enables a patient to capture a 30-second ECG recording with its credit-card-sized, cable-free device, regardless of where they are. The HeartBeam-HeartNexus collaboration makes board-certified cardiologists available 24/7 to interpret the results for arrhythmia assessment and provide expert feedback directly to the patient or to a coordinating clinician. HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus (https://ibn.fm/yyz1i). The partnership will expand access to cardiologist-level ECG insights for…

ThursdayNov 13, 2025 10:00 am

Rarest Natural Element Promises to Revolutionize How Cancer is Treated

Scientists at Texas A&M University have unlocked a new way that involves leveraging the rarest natural element, astatine-211, to kill cancer cells. This form of radiotherapy eliminates malignant cells while leaving the healthy tissues surrounding the cancer unaffected. One of the biggest challenges that have plagued conventional cancer therapies like chemotherapy and radiotherapy is that the treatments are indiscriminate and impact both cancerous tissues and healthy cells. As a result, these treatments cause side effects that can often be very serious or even life-threatening. The use of astatine-211 promises to address this drawback of existing radiotherapy approaches. Astatine (a Greek…

TuesdayNov 11, 2025 10:00 am

US Senators Reach Deal to Reopen Government

A group of Senate Democrats has agreed to re-open the government, at least until January, without receiving a guarantee that their key demand of extending healthcare insurance subsidies will be met by GOP lawmakers. That breakthrough was secured after the Senate held a rare session on Sunday to chart a way out of the longest ever government shutdown in the history of the country. During that session, a number of centrist Democrats negotiated with GOP Senators and the Democrats promised to vote in favor of re-opening the government on condition that they were given a promise that the chamber would…

TuesdayNov 11, 2025 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology

The company was ranked second worldwide out of 243 companies evaluated in 12-lead ECG innovation in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system. HeartBeam’s intellectual-property foundation is a major reason for its placement. HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in…